01353nas a2200229   4500000000100000008004100001653001700042653001200059653002200071653003000093100001300123700002200136700001300158700001300171700001400184245015000198856006800348300001200416490000700428520067400435022001401109       2017                            d10aTherapeutics10aleprosy10aDrug Combinations10aCombined Modality Therapy1 aCruz RCS1 aBührer-Sékula S1 aPenna ML1 aPenna GO1 aTalhari S00aLeprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.  uhttp://www.scielo.br/pdf/abd/v92n6/0365-0596-abd-92-06-0761.pdf  a761-7730 v923 a<p>In this review, the most relevant and current epidemiological data, the main clinical, laboratory and therapeutical aspects of leprosy are presented. Detailed discussion of the main drugs used for leprosy treatment, their most relevant adverse effects, evolution of the therapeutic regimen, from dapsone as a monotherapy to the proposed polychemotherapy by World Health Organization (WHO) can be found in this CME. We specifically highlight the drug acceptability, reduction in treatment duration and the most recent proposal of a single therapeutic regimen, with a fixed six months duration, for all clinical presentations, regardless of their classification.</p>
  a1806-4841